Ultomiris meets primary endpoint in Phase III trial for IgAN
Ultomiris showed a statistically significant reduction of proteinuria in adults with immunoglobulin A nephropathy in the Phase III I CAN trial.
Asset / Drug
Drug and asset intelligence for Ultomiris with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.